Our news

Slovenia joining MELD-ATG

17. August 2021

As from today, our Slovenian INNODIA partner can start recruitment for the MELD-ATG study. That makes the Medical Center of the Ljubljana University the fifth center taking part in the intervention study. The aim of this trial is to test if the drug ATG (Anti Thymocyte Globulin) has the potential to keep the balance between attacking and regulating cells within the immune system, and thus to preserve insulin secretion.